Deals channel feed – Endpoints News

Deals channel feed

Who else wanted to buy Iveric? Before the $5.9B Astellas deal, five biopharma companies took a look

3 years ago

Back Bay makes deal with Norway's DNB in banking and advisory partnership

3 years ago

Novartis beefs up gene therapy pipeline, spending $87.5M on an Avrobio therapy

3 years ago

Ironwood to buy VectivBio in $1B all-cash deal to expand rare gastrointestinal pipeline

3 years ago

Manufacturing-centric SPAC makes a deal to combine with French CDMO

3 years ago

Mustang Bio to sell Massachusetts CAR-T manufacturing facility

3 years ago

EyePoint sells remaining rights to eye implant, pivots to tackle anti-VEGFs

3 years ago

AstraZeneca beefs up cell therapy tool kit with gene editing deal

3 years ago

Amgen's CEO says he's 'confident' their $28B deal with Horizon can close despite FTC lawsuit

3 years ago

SPAC for 2025 BLA: Non-viral gene therapy biotech enGene, steered by ex-Mythic leaders, finds Forbion blank check

3 years ago

Lilly’s Prevail taps Jennifer Doudna's spinout Scribe Therapeutics for neuro genetic medicines

3 years ago

Astellas, Sony partner up for antibody-drug conjugate platform to create 'better performing' drugs

3 years ago

FTC sues to block $28B Amgen-Horizon deal, in move that will send shockwaves through biopharma M&A

3 years ago

UniQure sells part of Hemgenix royalty for $400M cash

3 years ago

Adding to ADC portfolio, AstraZeneca enters potential $600M licensing deal with Chinese startup

3 years ago

Italy's Angelini Pharma teams up with JCR on blood-brain barrier deal

3 years ago

BioNTech and Matinas end oral mRNA delivery collaboration

3 years ago

Exclusive: After winning legal battle, former PhaseBio investor finds US buyer for its PhIII drug to reverse Brilinta

3 years ago

CRO deal space continues to buzz as Genesis Drug Discovery buys JSS Medical Research

3 years ago

CRO Syneos Health to be acquired by a group of private equity firms for $7B+

3 years ago

Sobi swoops in with $1.7B buyout for a biotech with an approved JAK inhibitor, but low on cash

3 years ago

Bayer follows Novartis' footsteps in inking radiopharma pact with Bicycle, paying $45M cash upfront

3 years ago

Amgen enlists TCR startup TScan to work on Crohn's in deal potentially worth $500M+

3 years ago

Gilead's M&A streak carries on with buyout of private PARP1, autoimmune biotech

3 years ago

First page Previous page 35 36 373839 40 41 Next page Last page